-
Top 4 Small-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio (PDLI, EXEL, SHP, VPHM)
Tuesday, December 28, 2010 - 6:26am | 118Below are the top small-cap biotechnology stocks on the NYSE and the NASDAQ in terms of PEG ratio. PDL BioPharma Inc (NASDAQ: PDLI) has a PEG ratio of 0.27. PDLI's trailing-twelve-month operating margin is 89.34%. Exelixis Inc (NASDAQ: EXEL) has a PEG ratio of 0.33. EXEL's trailing-twelve-month...
-
FDA Rejection Sends pSivida Shares Down 20.1% (PSDV)
Monday, December 27, 2010 - 3:36pm | 180Shares of pSivida Corp. (Nasdaq: PSDV) are currently down 20.1% at $5.08 per share during Monday afternoon trading. pSivida Corporation reported after the market closed on Thursday that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New...
-
Affymetrix Shares Up 4.8% (AFFX)
Monday, December 27, 2010 - 1:05pm | 147Shares of Affymetrix, Inc. (Nasdaq: AFFX) are trading up 4.8% at $5.24 per share during the Monday afternoon trading session. The day's trading range for shares of Affymetrix, Inc has been between $5.02 and $5.36 per share. Analysts covering Affymetrix, Inc. (AFFX) stock give it a consensus price...
-
Afternoon Market Update
Monday, December 27, 2010 - 1:05pm | 173Oil and gas stocks dropped, along with the wider equity market. The NYSE Arca Oil Index (XOI) fell about 0.49%, while the NYSE Arca Natural Gas Index (XNG) dropped about 0.63%. The Philadelphia Oil Service Sector Index (OSX) dipped about 1.16%. Crude-oil for February delivery dropped $0.65 to $90....
-
Options Brief: pSivida Corp. (PSDV)
Monday, December 27, 2010 - 12:19pm | 78Shares of pSivida Corp. (NASDAQ: PSDV) are lower on the session by 20.75%, trading at $5.03. Overall put volume is now running at 6.41x the daily average, with 62% of all puts traded being purchases on the offer. 1,045 contracts have traded on the session so far. pSivida Corp., together with its...
-
Setback for Cumberland Pharma - Analyst Blog
Monday, December 27, 2010 - 11:00am | 358Recently, Cumberland Pharmaceuticals, Inc. (CPIX) encountered a huge blow on the US Food and Drug Administration (FDA) refusing to approve its liver failure injectable drug, Acetadote, for an additional indication due to insufficiency of data. Acute liver failure is associated with a high...
-
Vivus Seeks EU Nod for Qnexa - Analyst Blog
Monday, December 27, 2010 - 10:30am | 609Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric...
-
Setback for Cumberland Pharma - Analyst Blog
Monday, December 27, 2010 - 10:30am | 358Recently, Cumberland Pharmaceuticals, Inc. (CPIX) encountered a huge blow on the US Food and Drug Administration (FDA) refusing to approve its liver failure injectable drug, Acetadote, for an additional indication due to insufficiency of data. Acute liver failure is associated with a high...
-
Thermo Fisher Scientific Completes Acquisition of Lomb Scientific
Monday, December 27, 2010 - 10:00am | 37Thermo Fisher Scientific Inc. (NYSE: TMO) has completed its previously announced acquisition of Lomb Scientific, a well-known provider of laboratory chemicals, consumables and instruments in Australia and New Zealand.
-
Vivus Seeks EU Nod for Qnexa - Analyst Blog
Monday, December 27, 2010 - 9:45am | 609Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric...
-
Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)
Monday, December 27, 2010 - 9:43am | 139pSivida Corp (NASDAQ: PSDV) dipped 27.67% to $4.60 in the pre-market session. PSDV confirmed that its collaborative partner, Alimera Sciences (NASDAQ: ALIM) has received a complete response letter (CRL) from FDA for its ILUVIEN drug. Tesla Motors Inc (NASDAQ: TSLA) lost 3.19% to $29.13 in the pre-...
-
A Peek Into The Market Before The Trading Starts
Monday, December 27, 2010 - 9:06am | 571Pre-open movers US stock futures are lower this morning as China lifted its key lending and deposit rates. Futures for the Dow Jones Industrial Average dropped 40 points to 11,482 and those for the S&P 500 index fell 5.70 points to 1,247. Futures for the Nasdaq 100 index dipped 4.75 points to 2...
-
Oppenheimer Has Outperform Rating On Alimera Sciences (ALIM)
Monday, December 27, 2010 - 8:16am | 166Oppenheimer & Co. has an Outperform rating and $14 price target on shares of Alimera Sciences Inc (NASDAQ: ALIM). In a note sent to clients, Oppenheimer writes, "On 12/23, ALIM received an FDA complete response letter (CRL), delaying approval of Iluvien for diabetic macular edema (DME)....
-
Certriad Development Discontinued - Analyst Blog
Thursday, December 23, 2010 - 11:06am | 425Abbott Labs (ABT) and AstraZeneca (AZN) recently announced that they no longer intend to continue with the development of Certriad, a fixed-dose, single pill formulation of Abbott Lab's next-generation triglyceride lowering pill, TriLipix and AstraZeneca's powerful statin drug, Crestor. The...
-
Certriad Development Discontinued - Analyst Blog
Thursday, December 23, 2010 - 10:30am | 425Abbott Labs (ABT) and AstraZeneca (AZN) recently announced that they no longer intend to continue with the development of Certriad, a fixed-dose, single pill formulation of Abbott Lab's next-generation triglyceride lowering pill, TriLipix and AstraZeneca's powerful statin drug, Crestor. The...